AZTREONAM AS MONO-THERAPY IN INFECTIONS OF URINARY-TRACT WITH SYSTEMIC REPERCUSSION OF PATIENTS WITH RELATIVE CONTRAINDICATION FOR THE USE OF AMINOGLYCOSIDE

A comparative study has been performed to evaluate the clinical effica cy and safety of aztreonam in the treatment of urinary tract infection s with systemic affectation, in a group of patients who showed a relat ive contraindication to be treated with aminoglycosides. The group stu died was formed by 30 patients (21 females and 9 males). Mean age of s aid group was 78 years and percentage of patients over 65 years was 93 %. Moreover, 53.3% of patients showed nephropathy, 30% diabetes mellit us and 16.6% hearing disorders. Responsible germ of the infection was identified through blood and urine culture in 24 patients (80%) being the most frequent isolated E. Coli (60%). The cure rate was of 76.6% a nd improvement rate was 13.3%. Three deaths happened on the studied gr oup (10%). In a patient superinfection due to Enterococcus was detecte d. There were no significative adverse effects (Hyper-sensibility reac tions, hematological disorders, nephrotoxicity or hepatotoxicity). Azt reonam could be an efficacious alternative in the treatment of urinary infection with systemic affectation, caused by gram negative germs, s howing low toxicity.